Genomic Vision: New Preliminary Results Place HPV Integration Test as Potential Biomarker for Prognosis of Cervical Cancer
10 Décembre 2018 - 7:45AM
Business Wire
New preliminary data of EXPL-HPV-002 have been
presented at EUROGIN 2018, the international multidisciplinary HPV
congress in Lisbon, Portugal
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), company
specialized in the development of diagnostic tests for the early
detection of cancers and hereditary diseases, and applications for
life sciences research, announced today that it has shown new
promising preliminary results during Eurogin 2018, the
international multidisciplinary HPV congress which took place from
December 2 to 5, 2018 in Lisbon, Portugal.
During an oral presentation untitled “EXPL-HPV-002 Association
between integration of high-risk HPV genomes, detected by molecular
combing, and the severity and/or clinical outcome of cervical
lesions”, Florence Mahé, Director of Medical Research of Genomic
Vision, revealed new trends from the longitudinal study currently
conducted in Czech Republic that show the importance of the HPV
integration parameter in the evolution of the patient from low
grade to a higher grade of lesions within a 18-month period.
The data showed that the percentage of patients becoming high
grade after 6, 12 or 18 months is more important in the category
with a high integration rate of HPV.
Aaron Bensimon, co-founder and CEO of Genomic Vision,
declared: “These new preliminary results could place our HPV
integration test as a potential biomarker candidate for prognosis
of cervical cancer. Then, our test could help clinicians to
stratify the risk of progression to high-grade neoplasia and cancer
and finally to improve patients care”.
ABOUT GENOMIC VISIONGENOMIC VISION is a company
specialized in the development of diagnostic solutions for the
early detection of cancers and serious genetic diseases and tools
for life sciences research. Through the DNA Molecular Combing, a
strong proprietary technology allowing to identify genetic
abnormalities, GENOMIC VISION stimulates the R&D productivity
of the pharmaceutical companies, the leaders of the diagnostic
industry and the research labs. The Company develops a robust
portfolio of diagnostic tests (breast, ovarian and colorectal
cancers, myopathies) and analysis tools (DNA replication,
biomarkers discovery, gene editing quality control). Based near
Paris, in Bagneux, the Company has approximately 50 employees.
GENOMIC VISION is a public listed company listed in compartment C
of Euronext’s regulated market in Paris (Euronext: GV - ISIN:
FR0011799907). For further information, please visit
www.genomicvision.com
Membre des indices CAC® Mid & Small et
CAC® All-Tradable
FORWARD LOOKING STATEMENTThis press release contains
implicitly or explicitly certain forward-looking statements
concerning Genomic Vision and its business. Such forward-looking
statements are based on assumptions that Genomic Vision considers
to be reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
“Risk Factors” section of the reference document dated March 28,
2017, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181209005028/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel.: +33 1 49 08 07 50investisseurs@genomicvision.com
Ulysse CommunicationPress RelationsBruno
ArabianTel.: +33 1 42 68 29 70barabian@ulysse-communication.com
NewCapInvestor Relations& Strategic
CommunicationsTel.: +33 1 44 71 94 94gv@newcap.eu
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Genomic Vision (EU:GV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024